Stock comparison
Collegium Pharmaceutical
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
COLL
Collegium Pharmaceutical
Market cap
$1.11B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | COLL | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 77B | LMAT |
| Benjamin Graham | 62D | 89A | LMAT |
| Philip Fisher | 40D | 81C | LMAT |
| Peter Lynch | 53D | 67B | LMAT |
| Joel Greenblatt | 28F | 56D | LMAT |
| Charlie Munger | 44D | 68D | LMAT |
| Terry Smith | 43D | 69D | LMAT |
Side-by-side metrics
| Metric | COLL | LMAT |
|---|---|---|
| Market cap | $1.11B | $2.23B |
| P/E (TTM) | 15.5x | 37.1x |
| EV/EBIT | 9.1x | 36.6x |
| ROIC (TTM) | 10.51% | 9.43% |
| Gross margin | 60.68% | 72.39% |
| Net margin | 9.41% | 24.35% |
| Revenue CAGR 5y | 29.58% | 12.75% |
| EPS CAGR 5y | -0.86% | 19.04% |
| Debt / Equity | 2.6x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
COLL leads on
- EV/EBIT9.1xvs 36.6x+75%
- P/E (TTM)15.5xvs 37.1x+58%
- Revenue CAGR 5y29.58%vs 12.75%+57%
- ROIC (TTM)10.51%vs 9.43%+10%
LMAT leads on
- EPS CAGR 5y19.04%vs -0.86%+105%
- Dividend yield0.84%vs 0.0%+100%
- Debt / Equity0.5xvs 2.6x+82%
- Net margin24.35%vs 9.41%+61%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.